Isoflavone-derived drug inhibits prostate tumor metastasis
The Ninth Annual American Association for Cancer Research Frontiers in Cancer Prevention Research Conference held November 7 to 10, 2010 in Philadelphia was the site of a presentation by Raymond Bergan, MD of Northwestern University concerning the development of a pharmaceutical agent based on the soy isoflavone genistein which could help prevent the metastasis of prostate cancer. While localized prostate cancer has a very high rate of treatment success, disease that has metastasized to other areas of the body has a much poorer prognosis.
In a phase II study implemented by Dr Bergan and his associates which involved the administration of genistein to men with localized prostate cancer prior to surgery, an increase in the expression of genes that suppress metastasis and decreased expression of genes that enhance it were found in the prostate tissue of subjects that received the compound. "This is the first time that it has been possible to inhibit prometastatic pathways in humans by targeted therapeutics for any cancer type," the researchers announced.
Acting on these findings, Dr Bergan's team sought to develop a new drug with improved efficacy and high specificity. The compound they developed, known as KBU2046, has greater anti-invasion efficacy compared to genistein, while lacking the potential for estrogenic activity.
“The first step is to see if the drug has the effect that you want on the cells and the prostate, and the answer is ‘yes, it does,’” stated Dr Bergan, who is the director of experimental therapeutics at Northwestern's Lurie Comprehensive Cancer Center. “All therapies designed to stop cancer cell movement that have been tested to date in humans have basically failed because they have been ineffective or toxic. If this drug can effectively stop prostate cancer from moving in the body, theoretically, a similar therapy could have the same effect on the cells of other cancers.”
"We are in the process of bringing KBU2046 into the clinic, with the goal of preventing death from the second most common cause of cancer related death in men," the researchers conclude.
Once a diagnosis of prostate cancer (PC) is established by means of tissue biopsy and microscopic findings showing PC, the foundation of the medical record should have further information added to it to allow for an even greater understanding of the patient's true status. In this context, status refers to the actual extent of disease, or stage of disease. Is the PC really confined to the prostate gland or does it penetrate the capsule of the prostate or perhaps invade local surrounding tissues such as the seminal vesicles and nearby lymph nodes? Are there any clues that the PC has spread or metastasized to more distant lymph nodes or bone?
The orientation of most specialists will be toward recommending a local therapy to eradicate PC within the gland. This is the essence of the reasoning behind the surgical removal of the prostate—radical prostatectomy (RP). The other approaches toward treating PC with curative intent may be slightly more regional, but most are still designed to primarily treat the prostate gland. For example, external beam radiation therapy (EBRT) will include not only the prostate gland itself, but also a margin around the gland to kill any tumor cells that may be in this area trying to escape and spread to more distant sites. The same is true for the iceballs created by cryosurgery. The critical concept here is that local measures treat local disease. The determination of the true extent or stage of the disease is one of the critical variables in the strategy of successful treatment of PC. For example, if the disease is present outside the prostate gland in tissues such as the seminal vesicle or nearby regional lymph nodes (the obturator or internal iliac lymph nodes), an RP will have a significantly diminished chance in curing the patient with PC. The same is true for radiation therapy (RT) or cryosurgery. For such therapies to have a great chance of a cure, the cancer must be within the scope of the scalpel, within the boundaries of the radiation ports of therapy, and within the periphery of the iceball(s) created by cryosurgery.
An additional limiting factor for radiation therapy and cryosurgery is the amount of PC. The tumor volume has a bearing on the ability of RT or cryosurgery to destroy the entire tumor mass. This second variable in the equation may relate to the penetrating ability of the radiation particle used (photon < proton < neutron) or to the understanding that the core of a large tumor has a diminished oxygen supply (a hypoxic center) that confers resistance (called radioresistance) to the treatment. This actually may not be as critical a factor in cryosurgery as it is in RT.
Mitochondrial Basics with BioPQQ™
Mitochondrial Basics brings together cutting-edge mitochondrial energizers, including the most exciting nutrient to emerge in recent years: pyrroloquinoline quinone, or PQQ. The three ingredients in Mitochondrial Basics are:
PQQ.This breakthrough micronutrient has recently been shown to trigger mitochondrial biogenesis—the growth of new mitochondria in aging cells! PQQ also activates genes involved in protecting the delicate structures within the mitochondria.
R-lipoic acid.The detrimental effects of free radicals comprise one of the chief obstacles to optimal mitochondrial energy production. Published studies confirm R-lipoic acid’s power to promote mitochondrial bioenergetics while simultaneously blunting free radical activity. Mitochondrial Basics contains the superior Bio-Enhanced® R-lipoic acidand is in a proprietary microencapsulated form for better absorption.
Acetyl-L-carnitine arginate.Fats are shuttled into the mitochondria for metabolic combustion by the amino acid carnitine. The acetylated form of carnitine helps to facilitate more efficient utilization of fats than carnitine alone.
Cognitex Basics is a convenient and cost effective basic version of Life Extension's original Cognitex formula. Although the original Cognitex represents the best cost per milligram value, Cognitex Basics supplies clinically evaluated doses of alpha-glyceryl phosphoryl choline (alpha-GPC) and phosphatidylserine, both of which are critical to proper neurotransmitter function and optimal cognitive health.
Alpha-glyceryl phosphoryl choline is a precursor to the neurotransmitter acetylcholine, which is naturally present in all the body’s cells and plays important roles in the brain. A decline in acetylcholine levels coincides with advancing age and is a hallmark of neurodegeneration.
Phosphatidylserine (PS) is a crucial building block in the brain. In fact, brain tissues are especially rich in this nutrient. However, aging causes a decline in the PS content of cells throughout the body including brain cells, which can lead to cognitive decline.
BioPQQ™ is a trademark of MGC (Japan). Bio-Enhanced® is a registered trademark of Geronova Research, Inc. Crominex®3+ is a registered trademark of Natreon, Inc. CinSulin® is a registered trademark of Tang-An Medical Ltd., manufactured under US patent #6,200,569. Lipowheat™ is a trademark of LAVIPHARM Group of Companies